Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2019-06-16 Share Issue/Capital Cha…
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Appendix 3B 12 pages 294.5KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including unlisted options, their terms, issue prices, and compliance with ASX rules. It includes sections on the number and class of securities issued, security holder approvals, quotation requests, and calculation of placement capacity under ASX rules. The document is a formal announcement related to new share issues and capital changes, specifically an Appendix 3B form used in Australian securities regulation for notifying the market of new securities issued. It does not contain financial statements, earnings data, management discussion, or other report content. Therefore, it fits the category of a Share Issue/Capital Change announcement rather than a full financial report or other filing types.
2019-06-16 English
Notice of General Meeting/Proxy Form 37 pages 1.0MB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Notice of General Meeting and Explanatory Memorandum for Botanix Pharmaceuticals Limited. It includes details about resolutions to be voted on at a shareholder meeting, such as granting incentive options to executives and approval of termination benefits. It contains proxy voting instructions and detailed explanations of the resolutions. This type of document is typically sent to shareholders to inform them about the agenda and provide information necessary to make voting decisions at a general meeting. It is not a report of financial results, audit, or earnings, nor is it a transcript or presentation. It is not a voting results announcement but rather the notice and explanatory materials before the meeting. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is the full notice and explanatory memorandum, not just an announcement of a report publication or a short regulatory filing.
2019-06-16 English
Advisory Board Presentation on Psoriasis Market Opportunity 19 pages 1.7MB
Investor Presentation Classification · 95% confidence The document is an ASX/Media Release dated 14 June 2019 from Botanix Pharmaceuticals presenting an Advisory Board Presentation on the Psoriasis Market Opportunity. It includes detailed market analysis, clinical pipeline updates, and strategic insights related to psoriasis treatments. The content is structured as a presentation with multiple slides, charts, and data points focusing on market opportunity and clinical development status. There is no indication that this is a full financial report, earnings release, or regulatory filing. It is a detailed presentation aimed at investors and stakeholders about the company's market and product pipeline. Therefore, the document best fits the category of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification rather than a brief announcement or regulatory filing.
2019-06-13 English
Appendix 3B 12 pages 294.2KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including unlisted options, their terms, issue prices, and compliance with ASX rules. It includes sections on the number and class of securities issued, security holder approvals, quotation of securities, and calculation of placement capacity under ASX rules. The document is a formal announcement related to new share issues and capital changes, specifically an Appendix 3B form used in Australian securities regulation for notifying the market of new issues of securities. It does not contain financial statements, management discussion, or audit information, nor is it a report or presentation. Therefore, it fits the category of a Share Issue/Capital Change announcement.
2019-06-12 English
Appendix 3B Amended 12 pages 294.6KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including unlisted options, their terms, issue prices, and compliance with ASX rules. It references specific ASX rules (e.g., Rule 7.1, 7.1A) and includes sections on quotation of securities and placement capacity calculations. The content is regulatory in nature, focused on announcing and detailing a new share issue and application for quotation of additional securities. This matches the definition of a Share Issue/Capital Change announcement, which covers new share issues and capital structure changes. The document is lengthy (15,000 characters) and contains substantive details about the securities issued, not merely a brief announcement or a report publication notice. Therefore, the appropriate classification is 'SHA' (Share Issue/Capital Change).
2019-06-12 English
Botanix at the Jefferies Healthcare Conference 30 pages 1.9MB
Investor Presentation Classification · 95% confidence The document is an ASX/Media Release dated 6 June 2019 from Botanix Pharmaceuticals. It announces the company's participation and presentation at the 2019 Jefferies Healthcare Conference. The content includes an overview of the company, its clinical pipeline, market potential, technology, and product candidates. The document is a detailed investor presentation focusing on the company's financials, strategy, clinical progress, and market position. There are no financial statements or quarterly results reported, nor is it an announcement of voting results, management changes, or legal matters. The presence of slides and detailed company and product information aligns with an Investor Presentation. The document length is substantial (15,000 characters), indicating it is the presentation itself, not just an announcement of a report. Therefore, the appropriate classification is Investor Presentation (IP).
2019-06-05 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.